Back to top
more

Penumbra (PEN)

(Delayed Data from NYSE)

$233.30 USD

233.30
525,994

+4.43 (1.94%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $233.26 -0.04 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's How Labcorp (LH) is Placed Ahead of Q2 Earnings Release

by Zacks Equity Research

Labcorp's (LH) second-quarter 2024 performance is expected to reflect the robust execution of strategic priorities and solid business performances.

Here's Why Penumbra (PEN) is a Strong Growth Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Hologic's (HOLX) Surgical Business Set to Propel Q3 Earnings

by Zacks Equity Research

Hologic (HOLX) is likely to have delivered impressive performances across the GYN Surgical and Breast Health businesses in the third quarter of fiscal 2024.

Will Patient Volumes Drive Universal Health's (UHS) Q2 Earnings?

by Zacks Equity Research

Universal Health's (UHS) Q2 performance is likely to gain from strong performances in its Acute Care Hospital Services and Behavioral Health Care Services segments.

Penumbra (PEN) Soars 3.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Penumbra (PEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Looking for a Growth Stock? 3 Reasons Why Penumbra (PEN) is a Solid Choice

by Zacks Equity Research

Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.

How Much Upside is Left in Penumbra (PEN)? Wall Street Analysts Think 34.22%

by Zacks Equity Research

The consensus price target hints at a 34.2% upside potential for Penumbra (PEN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Here's Why Holding Align Technology (ALGN) Stock Could Pay Off

by Zacks Equity Research

Align Technology's (ALGN) Invisalign portfolio expansion efforts spark optimism.

Why Penumbra (PEN) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Is Penumbra (PEN) Down 4.8% Since Last Earnings Report?

by Zacks Equity Research

Penumbra (PEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

GMED or PEN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

GMED vs. PEN: Which Stock Is the Better Value Option?

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Penumbra (PEN) Q1 Earnings Lag Estimates, Margins Expand

by Zacks Equity Research

Penumbra's (PEN) Thrombectomy product category shows encouraging growth trends, reflecting strong momentum in CAVT products.

Shaun Pruitt headshot

Don't Overlook These Top Medical Stocks as Q1 Earnings Approach

by Shaun Pruitt

Several top-rated Zacks Medical sector stocks are standing out ahead of their quarterly reports on Tuesday, May 7.

Artivion (AORT) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Artivion (AORT) delivered earnings and revenue surprises of 200% and 5.56%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Penumbra's (PEN) New Launch to Enhance Blood Clot Removal

by Zacks Equity Research

Penumbra's (PEN) latest offering is likely to enable physicians to restore blood flow more quickly and further minimize blood loss.

GMED vs. PEN: Which Stock Is the Better Value Option?

by Zacks Equity Research

GMED vs. PEN: Which Stock Is the Better Value Option?

Here's Why Penumbra (PEN) is a Strong Growth Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why You Should Retain Penumbra (PEN) Stock for Now

by Zacks Equity Research

Investors are optimistic about Penumbra (PEN) on strength exhibited in the Thrombectomy business and global expansion.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Penumbra (PEN) Gains From Innovation, Mounting Costs Ail

by Zacks Equity Research

Penumbra (PEN) expects to materially increase both revenues and profitability in the company's international business in the next three years and beyond.

Why Penumbra (PEN) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Penumbra (PEN) Q4 Earnings Top Estimates, Margins Increase

by Zacks Equity Research

Penumbra's (PEN) Q4 revenues register year-over-year growth driven by robust U.S. thrombectomy sales.

Penumbra (PEN) Q4 Earnings Beat Estimates

by Zacks Equity Research

Penumbra (PEN) delivered earnings and revenue surprises of 7.04% and 1%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?